Boris Melloni1,2, Line Mounier1, Jean-Pierre Laaban3, Arnaud Chambellan4, Didier Foret1, Jean-François Muir1,5. 1. ANTADIR Federation, Paris, France. 2. Department of Pulmonology, Limoges University Hospital, Limoges, France. 3. Department of Pulmonology, AP-HP Cochin, Paris, France. 4. Chest Institute, Nantes University Hospital, "Movement, Interactions, Performance" Laboratory (EA 4334), Faculty of Sport Sciences, Nantes University, Nantes, France. 5. Department of Pulmonology and Respiratory Intensive Care, Rouen University Hospital, Rouen, France.
Abstract
BACKGROUND: The aetiologies of chronic respiratory failure (CRF) are moving in many western countries. Obesity-Hypoventilation syndrome (OHS) has become one of the most common indications of non-invasive ventilation (NIV) with Chronic Obstructive Pulmonary Diseases (COPD). Long-Term Oxygen Therapy (LTOT) technology is the treatment plan for CRF patients in the new era. OBJECTIVES: This study aimed to assess home-based care evolution in CRF patients on LTOT (LTOT) and/or NIV from the ANTADIR observatory. METHODS: A computerized database from 14 regional facilities was analysed (30% of French home-treated patients). Patient age, sex, aetiology, home respiratory devices were recorded between 2001 and 2015. RESULTS: By the end of 2015, 12,147 CRF patients received LTOT (40%), NIV (24%), LTOT + NIV (23%), continuous positive airway pressure (CPAP; 11%) or LTOT + CPAP (3%). Between 2001 and 2015, we observed a decrease of LTOT (63-40%) in the benefit of NVI ± LTOT (25-47%). Regarding the aetiology, we note a slight decrease in obstructive disease and a significant increase in restrictive disease, mainly due to OHS. The 10-year survival was better on NIV ± LTOT than on LTOT, for overall patients and for both obstructive and restrictive patients. The 10-year survival was better on NIV ± LTOT than on LTOT (35 vs. 10%, p < 0.05). In COPD patients on LTOT, a switch from conventional to new home devices was observed. Stationary LTOT systems were less prescribed, while portable/transportable -system, liquid oxygen and self-filling oxygen were increasingly prescribed. CONCLUSION: Our study confirmed changes in CRF aetiologies and home devices. OHS is now an important indication of NIV. Using new LTOT technologies changed home prescriptions in COPD patients.
BACKGROUND: The aetiologies of chronic respiratory failure (CRF) are moving in many western countries. Obesity-Hypoventilation syndrome (OHS) has become one of the most common indications of non-invasive ventilation (NIV) with Chronic Obstructive Pulmonary Diseases (COPD). Long-Term Oxygen Therapy (LTOT) technology is the treatment plan for CRF patients in the new era. OBJECTIVES: This study aimed to assess home-based care evolution in CRF patients on LTOT (LTOT) and/or NIV from the ANTADIR observatory. METHODS: A computerized database from 14 regional facilities was analysed (30% of French home-treated patients). Patient age, sex, aetiology, home respiratory devices were recorded between 2001 and 2015. RESULTS: By the end of 2015, 12,147 CRF patients received LTOT (40%), NIV (24%), LTOT + NIV (23%), continuous positive airway pressure (CPAP; 11%) or LTOT + CPAP (3%). Between 2001 and 2015, we observed a decrease of LTOT (63-40%) in the benefit of NVI ± LTOT (25-47%). Regarding the aetiology, we note a slight decrease in obstructive disease and a significant increase in restrictive disease, mainly due to OHS. The 10-year survival was better on NIV ± LTOT than on LTOT, for overall patients and for both obstructive and restrictive patients. The 10-year survival was better on NIV ± LTOT than on LTOT (35 vs. 10%, p < 0.05). In COPDpatients on LTOT, a switch from conventional to new home devices was observed. Stationary LTOT systems were less prescribed, while portable/transportable -system, liquid oxygen and self-filling oxygen were increasingly prescribed. CONCLUSION: Our study confirmed changes in CRF aetiologies and home devices. OHS is now an important indication of NIV. Using new LTOT technologies changed home prescriptions in COPDpatients.
Authors: Kyunghyun Song; Sei-Won Kim; Yun Su Sim; Tai Sun Park; Young Seok Lee; Jick Hwan Ha; Ji Young Park; Ki-Suck Jung; Sunghoon Park Journal: J Thorac Dis Date: 2021-07 Impact factor: 2.895
Authors: Babak Mokhlesi; Juan Fernando Masa; Jan L Brozek; Indira Gurubhagavatula; Patrick B Murphy; Amanda J Piper; Aiman Tulaimat; Majid Afshar; Jay S Balachandran; Raed A Dweik; Ronald R Grunstein; Nicholas Hart; Roop Kaw; Geraldo Lorenzi-Filho; Sushmita Pamidi; Bhakti K Patel; Susheel P Patil; Jean Louis Pépin; Israa Soghier; Maximiliano Tamae Kakazu; Mihaela Teodorescu Journal: Am J Respir Crit Care Med Date: 2019-08-01 Impact factor: 21.405